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Précis	The	 PIVAC-14	 conference	 brought	 together	 translational	 and	 clinical	 oncologists	 and	immunologists	who	provided	an	up-to-date	overview	of	 the	most	 recent	 advances	 in	 active	cancer	vaccination	and	adoptive	cell	therapy.	
	 	
	 2	
Abbreviations:	ACT	adoptive	cell	transfer	CDR	complementarity	determining	regions	CMM	canine	malignant	melanoma	CSC	cancer	stem	cells	DC	dendritic	cells	DTH	delayed-type	hypersensitivity	ECM	extracellular	matrix	ECT	electrochemotherapy	EP	electropulsation	HCC	hepatocellular	carcinoma	HCV	hepatitis	C	virus	HDAC	histone	deacetylases	HPV	human	papilloma	virus	IFN	interferon	Ii	MHC	class	II-associated	invariant	chain	protein	IL	interleukin	M2	alternatively	activated	macrophages	MDSC	myeloid-derived	suppressor	cells	PBMC	peripheral	blood	mononuclear	cells	PSA	prostate	specific	antigen	PTX3	pentraxin	3	ROS	reactive	oxygen	species	SPARC	secreted	protein	acidic	and	rich	in	cysteine	TAM	tumor-associated	macrophages	TCR	T	cell	receptor	TGF	tumor	growth	factor		TIL	tumor	infiltrating	lymphocytes	TNF	tumor	necrosis	factor	TRAIL-R	TNF-related	apoptosis-inducing	ligand	receptor	Treg	T	regulatory	cells	VEGF	vascular	endothelial	growth	factor		 	
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PIVAC-14,	 the	 fourteenth	 annual	 conference	 on	 Progress	 in	 Vaccination	 Against	 Cancer	(http://www.tati-group.de/pivac/)	 has	 been	 held	 September	 24-26,	 2014,	 at	 the	 Donna	Camilla	Savelli	Hotel	in	Rome.	More	than	110	attendees	presented	and	discussed	a	plethora	of	new	and	promising	results	in	a	relaxed	and	informal	atmosphere.		The	main	topics	covered	by	PIVAC-14	were:	cancer	immunoprevention;	the	role	of	the	tumor	microenvironment	 in	 determining	 immunotherapy	 outcomes;	 the	 use	 of	 comparative	oncology	 in	 predicting	 immunotherapy	 effectiveness;	 tumor	 escape	 mechanisms	 and	 the	latest	experimental	and	clinical	advances	in	various	vaccination	strategies,	including	peptide-,	dendritic	cell-	and	T	cell-based	vaccines.	Special	attention	was	paid	 to	DNA	vaccination	and	electrotransfer,	 which	 benefited	 from	 a	 dedicated	 section	 co-organized	 by	 COST	 Action	TD1104	 -	EP4Bio2Med,	a	European	network	of	 researchers	working	on	 the	development	of	electroporation-based	technologies	and	treatment	in	the	field	of	medicine,	biotechnology	and	environment	preservation	(see:	http://www.electroporation.net).		
The	promise	of	preventive	cancer	vaccines		Cancer	immunoprevention	has	demonstrated	its	efficacy	against	infection-associated	tumors	like	 those	 induced	 by	 the	 human	 papilloma	 virus	 (HPV),	 as	 overviewed	 by	 Aldo	 Venuti	(Regina	Elena	National	Cancer	 Institute,	Rome,	 Italy)	and	Marij	Welters	 (Leiden	University	Medical	 Center,	 Clinical	 Oncology,	 Leiden,	 Netherlands)	 in	 their	 lectures.	 Recently	 the	possibility	 to	 apply	 cancer-vaccines	 in	 a	 preventive	 setting	 against	 non-infection-related	cancers	has	 gained	 consensus	 and	 is	 now	considered	 the	next	 frontier	 in	 the	battle	 against	cancer.	 This	 was	 the	 main	 topic	 of	 Olivera	 J.	 Finn	 (University	 of	 Pittsburgh	 School	 of	Medicine,	Pittsburgh,	PA,	USA)	opening	lecture.	Most	therapeutic	cancer	vaccine	trials	have	so	far	 only	 furnished	 marginal	 results.	 So-called	 push-pull	 strategies,	 where	 vaccination	 is	combined	with	 the	administration	of	adjuvants,	 cytokines,	 immune	checkpoint	 inhibitors	or	other	strategies	 that	may	counteract	 tumor-induced	 immunosuppression,	hold	 the	potential	to	 increase	 the	efficacy	of	 therapeutic	 cancer	vaccines.	These	 treatments	are	expensive	and	some	are	also	very	toxic.	A	practical	and	feasible	alternative	is	to	vaccinate	patients	in	the	pre-malignant	 setting,	 targeting	 antigens	 expressed	 by	 premalignant	 lesions.	 The	 hypothesis	 is	that	 the	 immune	 system	 will	 be	 less	 suppressed	 in	 the	 premalignant	 state.	 Finn	 and	coworkers	have	chosen	advanced	adenomas	of	the	colon	as	premalignant	precursors	of	colon	cancer	and	MUC1	antigen,	whose	expression	during	colon	cancer	development	increases	from	small	 adenomas	 to	 metastasis.	 Patients	 were	 vaccinated	 with	 a	 MUC1	 100mer	 peptide,	admixed	with	 the	TLR3	 agonist	Hiltonol®,	 after	 removal	 of	 the	polyps;	 the	 vaccine	 elicited	
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anti-MUC1	 IgG	 responses	 and	 long-term	 memory	 in	 50%	 of	 the	 patients.	 No	 correlation	between	 response	 and	HLA	 expression,	 age	 or	 gender	was	 found.	 However,	 the	 peripheral	blood	mononuclear	 cells	 (PBMC)	 of	 non-responders	 contained	 increased	 levels	 of	myeloid-derived	 suppressor	 cells	 (MDSC),	 but	 not	 of	 T	 regulatory	 cells	 (Treg)	 prior	 to	 vaccination,	which	 eventually	 impaired	 the	 response	 to	 the	 vaccine.	 In	 order	 to	 verify	 the	 presence	 of	other	 response	 predictive	 factors,	 responder	 and	 non-responder	 PBMC	 gene	 expression	profiles	were	analyzed	 in	pre-vaccination	PBMC.	 	Close	 to	350	genes	 involved	 in	 interferon	(IFN)	signaling,	innate	immunity	and	T	cell	pathways,	showed	completely	different	expression	in	responders	and	non-responders.	The	hypothesis	presented	was	that	responders	to	the	vaccine	had	previous	immune	memory	against	abnormal	MUC-1,	which	may	have	been	generated	during	viral	 infections	and	other	nonmalignant	acute	inflammatory	events,	and	the	vaccine	simply	acted	as	a	boost.	People	that	had	not	previously	had	acute	inflammation	due	to	viral	infections	had	low	levels	of	specific	T	cells	 and	 high	MDSC	 and	 did	 not	 respond	 to	 the	 vaccine.	 A	 new	multi-center,	 randomized,	placebo-controlled	 phase	 II	 efficacy	 trial	 of	 the	 MUC1	 prophylactic	 vaccine	 started	 in	 May	2014;	results	are	expected	in	3-5	years.			
Inflammation	and	extracellular	matrix	shape	the	tumor	microenvironment		While	acute	inflammation	may	have	a	positive	role	 in	predisposing	the	host	to	react	against	tumors	and	 respond	 to	 cancer	vaccines,	 chronic	 inflammation	 instead	 is	known	 to	promote	tumor	progression.	 	As	discussed	by	Alberto	Mantovani	 (Istituto	Clinico	Humanitas	 IRCCS,	University	 of	 Milan,	 Rozzano,	 Italy)	 in	 his	 opening	 lecture,	 there	 are	 two	 pathways	 that	connect	cancer	and	chronic	inflammation:	the	intrinsic	pathway,	in	which	the	genetic	events	that	cause	cell	transformation	force	the	transformed	cell	to	produce	inflammatory	mediators	and	 promote	 the	 generation	 of	 an	 inflamed	 tumor	 microenvironment;	 and	 the	 extrinsic	pathway,	 in	 which	 a	 preexisting	 inflammatory	 microenvironment	 increases	 the	 risk	 of	neoplastic	 transformation.	Both	pathways	 induce	the	production	of	 inflammatory	mediators	that	recruit	and	activate	various	leukocytes,	mainly	myeloid	cells,	which	in	turn	contribute	in	maintaining	 inflammatory	 conditions.	 A	 key	 role	 in	 the	 maintenance	 of	 the	 inflammatory	environment	is	played	by	tumor-associated	macrophages	(TAM)	that	display	the	alternatively	activated	(M2)	phenotype.	Patients	that	have	high	TAM	levels	generally	show	poor	prognosis.	Targeting	 TAM	 may	 therefore	 be	 an	 effective	 anti-tumor	 strategy.	 The	 anti-tumor	 agent	Trabectedin,	a	natural	product	derived	from	a	marine	tunicate	that	binds	the	minor	groove	of	DNA,	may	be	particularly	effective	in	this	context.	It	is	selectively	cytotoxic	for	monocytes	as	it	
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activates	an	extrinsic	apoptosis	pathway	 that	 is	dependent	on	 tumor	necrosis	 factor	 (TNF)-related	apoptosis-inducing	ligand	receptor	(TRAIL-R).	Besides	depleting	macrophages	in	vivo,	Trabectedin	 also	 significantly	 reduces	 the	 expression	 of	 vascular	 endothelial	 growth	 factor	(VEGF)	and	of	the	chemokine	CCL2	in	tumor	vessels,	thereby	limiting	tumor	angiogenesis	as	well	 as	monocyte	 recruitment	 and	 differentiation	 into	 tumor-promoting	 TAM.	 Another	 key	component	 of	 cancer-related	 inflammation	 is	 the	 complement	 system.	 Mantovani	 and	 co-workers	have	recently	shown	that	a	molecule	from	the	interleukin	(IL)1-R	family,	the	humoral	pattern	 recognition	 molecule	 Pentraxin	 3	 (PTX3),	 protects	 against	 cancer	 development	 by	regulating	 complement-dependent	 tumor-promoting	 inflammation.	 PTX3	 expression	 in	human	 tumors	 is	 frequently	 inhibited	 by	 gene	methylation.	 PTX3	 deficient	 (PTX	 3-/-)	 mice	have	increased	susceptibility	to	chemically	induced	carcinogenesis	(earlier	tumor	appearance,	increased	growth	and	angiogenesis,	early	increase	in	TAM,	increased	p53	mutations	and	gene	instability	 in	 tumor	 cells).	 PTX3	 deficiency	 is	 also	 associated	 with	 increased	 complement	activation	 at	 the	 tumor	 site	 and	 increased	 cancer-related	 inflammation.	 Moreover,	 C3	deficiency,	C5aR	inhibition	and	macrophage	recruitment	inhibition	in	tumors	all	significantly	reduce	 susceptibility	 to	 3-methylcolanthrene-induced	 carcinogenesis	 in	 PTX3-/-	mice.	 These	data	bring	to	light	a	new	connection	between	inflammation	and	cancer	by	showing	that	PTX3,	an	effector	molecule	in	innate	immunity,	may	act	as	an	extrinsic	oncosuppressor.	The	key	role	of	 the	extracellular	matrix	(ECM)	 in	shaping	the	tumor	microenvironment	was	discussed	by	Mario	Paolo	Colombo	(Istituto	Nazionale	Tumori,	Milan,	Italy).	He	showed	that	four	 breast	 cancer	 prognostic	 groups	 can	 be	 identified	 according	 to	 differing	 ECM	 gene	expression	 enrichment	which	 leads	 to	 different	 ECM	 signatures.	 The	most	 prominent	 gene	that	was	 overexpressed	 in	 the	 signature	 and	which	 identifies	 high-grade	 tumors	with	 poor	response	 to	 therapy	 encodes	 the	 Secreted	 Protein	 Acidic	 and	 Rich	 in	 Cysteine	 (SPARC),	 an	ECM	 regulator	 that	 is	 expressed	 in	 vivo	 by	 both	 tumor	 and	 stromal	 cells.	 SPARC	overexpression	 triggers	 the	 epithelial-to-mesenchymal	 transition,	 tissue	 invasion	 and	regulates	 the	 recruitment	 and	effector	 function	of	myeloid	 infiltrating	 cells.	 	 Indeed,	 SPARC	regulates	collagen	assembly	that	in	turn	delivers	inhibitory	signals	through	its	receptor,	LAIR-1,	which	 is	expressed	by	myeloid	cells,	particularly	neutrophils.	This	 is	 in	 line	with	 the	role	SPARC	 plays	 in	 lymphoid	 tissue	 homeostasis.	 Stromal	 cells,	 which	 are	 unable	 to	 secrete	SPARC,	 induce	 an	 alteration	 in	 the	 hematopoietic	 niche	 that	 favors	 myeloid	 precursor	expansion	in	the	bone	marrow.	SPARC	deficiency	alters	mesenchymal	follicular	dendritic	cell	networking	 in	 secondary	 lymphoid	 organs	 and	 impairs	 humoral	 immunity	 while	 also	promoting	lymphomagenesis	in	persistent	lymphoid	tissue	homeostasis	perturbation.	Faulty	
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ECM	organization	may	lead	to	the	emergence	of	otherwise	silent	genetic	defects	that	in	turn	lead	to	the	development	of	hematologic	and	solid	malignancies	which	act	on	several	aspects	of	the	 tumor	 immune	microenvironment	 and	 thus	 influence	 almost	 all	 the	 characteristics	 that	tumor	 cells	 need	 to	 acquire	 if	 they	 are	 to	 become	 fully	 tumorigenic.	 SPARC	 and	 the	 other	matricellular	proteins	are	key	players	in	these	events	and	act	as	the	main	regulators	of	ECM	remodeling	during	tumorigenesis	and	endow	proper	immune	regulatory	functions.		
Lessons	from	phase	I/II	clinical	trials	Active	 immunotherapy	 is	emerging	as	a	potential	 therapeutic	approach	 for	prostate	 cancer.	Constantin	 N.	 Baxevanis	 (Cancer	 Immunology	and	Immunotherapy	Center,	St	Savas	Cancer	Hospital,	Athens,	Greece)	summarized	the	results	of	the	clinical	trial	in	prostate	cancer	that	he	has	 performed	 using	 the	 AE37	 cancer	 vaccine;	 a	 15mer	 peptide	 (776-790,	GVGSPYVSRLLGICL)	 from	 the	 intracellular	 domain	 of	 the	 HER2	 protein	 that	 is	 chemically	liked	to	a	tetramer	(LRMK)	from	the	MHC	class	II-associated	invariant	chain	(Ii)	protein.	The	AE37	vaccine	was	safe	and	could	induce	HER-2/neu–specific	cellular	immune	responses	and	clinical	 efficacy	 in	patients.	Retrospective	 analyses	 showed	 that	pre-vaccine	 levels	of	 tumor	growth	 factor	 (TGF)-β	 and	 IFN-γ	 displayed	 an	 inverse	 correlation	 with	 immunological	responses	to	the	AE37	vaccine,	and	clinical	efficacy.	Low	pre-existing	TGF-β	and/or	high	IFN-
γ 	 levels	 are	 prognostic	 factors	 for	 overall	 survival.	 Vaccine-induced	 delayed-type	hypersensitivity	(DTH)	has	also	a	prominent	role	as	a	prognostic	 factor	 for	overall	survival.	Baxevanis	and	co-workers	also	found	that	patients	that	express	the	HLA-A24	and	HLA-DR11	alleles	showed	better	overall	 survival,	 low	TGF-β	 levels	and	high	DTH	and	 IFN-γ	responses.	On	the	other	hand,	HLA-A2	positive	patients	trended	towards	shorter	overall	survival.	When	AE37/DR11	 tetramers	 were	 used	 to	 evaluate	 the	 frequencies,	 phenotype	 and	 function	 of	vaccine-induced	CD4+	T	cells	in	patients	that	express	the	HLA-DR11	allele,	 it	was	found	that	AE37	vaccination	 induced	peptide-specific	 central	 and	effector	memory	cells	 as	well	 as	 low	numbers	 of	 Treg	 and	 exhausted	 (PD1+	 and	 CTLA4+)	 cells.	 Finally,	 they	 showed	pre-vaccine	increased	 frequencies	 of	 CD8+	T	 cells	 against	 the	HLA-A24-restricted	 peptide	 (152-161)	 of	the	prostate	specific	antigen	(PSA)	which	were	boosted	during	vaccination.	Such	an	increased	T	 cell	 immunity	 against	 PSA	was	 also	 positively	 correlated	with	 prolonged	 overall	 survival	reinvigorating	 the	 essential	 role	 of	 endogenous	 antitumor	 immunity	 for	 the	 therapeutic	management	of	prostate	cancer.					
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Per	 thor	 Straten	 (Center	 for	 Cancer	 Immune	 Therapy,	 Copenhagen	 University	 Hospital	Herlev,	 Denmark)	 reported	 that	 adoptive	 cell	 transfer	 (ACT),	 using	 tumor	 infiltrating	lymphocytes	(TIL),	has	provided	impressive	clinical	results	in	phase	I/II	clinical	trials	for	the	treatment	of	melanoma,	with	around	20%	giving	complete	lasting	responses.	However,	some	patients	do	not	respond	at	all	or	only	temporarily.	Therefore,	Per	thor	Straten	and	co-workers	have	comprehensively	monitored	the	patients	included	in	a	phase	I/II	study	which	is	ongoing	at	 their	 institution.	With	 this	 aim	 in	mind,	 they	 looked	 for	 all	 known	melanoma	 associated	immunogenic	peptides,	restricted	by	HLA-A1,	-A2,	-A3,	-A11	and	-B7,	and	found	174	peptides	that	were	used	to	study	recognition	by	TILs	using	tetramers.	The	testing	of	in	vitro	expanded	TIL	with	these	tetramers,	showed	that	TIL	cultures	had	surprisingly	low	frequencies	of	cancer	specific	T	cell	prior	to	administration.	When	TIL	were	tested	for	reactivity	against	autologous	or	HLA-A-matched	allogeneic	melanoma	cell	lines,	an	association	was	found	between	clinical	response,	 higher	 absolute	numbers	 of	 tumor-reactive	CD8+	T	 cells	 infused	 and	 their	 in	vivo	persistence.	The	next	steps	in	the	study	of	TIL	based	ACT	will	be	the	initiation	of	a	multicenter	phase	 III	 clinical	 trials.	 Moreover,	 various	 combination	 treatments	 will	 be	 tested,	 e.g.	combining	ACT	with	the	administration	of	IFN-α,	anti-	PD1	and	genetic	engineering	of	TIL	to	improve	 T	 cell	 homing	 to	 tumor	 sites	 and	 sustained	 functionality	 in	 a	 hostile	 tumor	microenvironment.	 Finally,	 the	 identification	 of	 other	 cellular	 sources,	 e.g.	 γδ	 T	 cells,	 may	imply	that	ACT	can	be	used	for	the	treatment	of	other	solid	tumors,	for	which	TIL	cannot	be	expanded	properly.	
Lindy	 Durrant	 (Scancell	 and	 University	 of	 Nottingham,	 Nottingham,	 UK)	 presented	 the	results	 of	 a	 phase	 I/II	 clinical	 trial	 of	 the	 SCIB1	 ImmunoBody®	 vaccine	 in	 stage	 III/IV	melanoma	patients.	ImmunoBody®	vaccines	are	DNA	vectors	that	encode	engineered	human	IgG1	 antibody	 molecules	 that	 target	 the	 high	 affinity	 FcγR1	 (CD64)	 receptor	 on	 activated	dendritic	 cells	 (DC).	 T	 cell	 epitopes	 are	 inserted	 into	 the	 complementarity	 determining	regions	(CDR)	of	the	antibody	framework	to	make	a	genetic	antigen/antibody	complex.	SCIB1	ImmunoBody®	has	3	epitopes	from	gp100	and	one	from	TRP-2	antigens	grafted	into	its	CDR.	A	vaccine	dose	of	0.4,	2,	4	or	8	mg	was	 injected	 intramuscularly	 in	patients	with	metastatic	disease	(Part	1),	a	dose	of	4	mg	was	injected	intramuscularly	in	patients	with	resected	disease	(Part	2)	and	electroporation	was	administered.	Trial	 results	demonstrate	 that	SCIB1	 is	 safe	and	 immunogenic.	 24/28	 patients	 developed	 melanoma-specific	 immune	 responses	 and	 a	dose	response	effect	was	evident;	5/11	(45%)	Part	1	patients	who	received	a	2-8	mg	dose	of	SCIB1	displayed	evidence	of	a	clinical	response	(reduction	 in	 tumor	size	or	complete	 tumor	
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destruction,	 progression	 free	 survival,	 stable	 disease);	 all	 14	 Part	 2	 patients	 are	 still	 alive,	show	a	median	survival	time	of	21	months	since	study	entry	and	only	3	have	progressed.	
Anne	Merete	 Tryggestad	 (Department	 of	 Cellular	Therapy,	Oslo	University	Hospital,	Oslo,	Norway)	described	a	phase	I/II	trial	of	adjuvant	therapeutic	vaccination	in	resected	prostate	cancer	patients	using	autologous	DC	loaded	with	mRNA	from	primary	prostate	cancer	tissues	in	combination	with	hTERT	and	survivin	mRNA.	Two	different	DC	maturation	protocols	were	used:	a	2	day	Jonuleit-maturation	cocktail	and	a	3	day	TLR7/8-maturation	cocktail.	Only	2	of	the	 18	 patients	 enrolled	 have	 so	 far	 experienced	 PSA	 relapses,	 3	 and	 9	 months	 after	vaccination	started.	Extensive	 immune	monitoring	 is	ongoing,	making	use	of	 the	autologous	tumor	cell	lines	established	from	each	patient	using	an	in-house	cell	culture	method.		
Increasing	the	effectiveness	of	immunotherapy	Several	 studies	 have	 demonstrated	 that	 vaccination	 induced	 T	 cells	 have	 an	 effector	phenotype.	However,	 these	cells	are	not	often	able	 to	kill	 tumors	 that	express	PD1	on	 their	surface.	This	fact	has	driven	Suzanne	Ostrand-Rosenberg	(University	of	Maryland	Baltimore	Country,	Baltimore,	MD,	USA)	 to	 investigate	novel	 strategies	 for	 neutralizing	PD1	mediated	immune	suppression,	as	she	reported	in	the	sixth	session,	chaired	by	Constantin	N.	Baxevanis.	She	hypothesized	that	CD80	on	T	cells	may	bind	to	PD-L1	on	tumor	cells	and	sterically	inhibit	its	 binding	 to	 PD1	 thus	 preventing	 PD-L1	 from	 causing	 apoptosis,	 anergy	 and	 tolerance	 in	activated	PD1+	T	cells.		At	the	same	time,	CD80	binding	to	CD28	could	provide	costimulation.	Indeed,	 a	 soluble	 form	of	CD80	binds	 to	 tumor	cell-expressed	PD-L1,	prevents	PD1	binding	and	maintains	PD1+	T	cell	activation.		It	appears	to	be	more	effective	than	PD1,	PD-L1	or	PD1-Fc	specific	antibodies.	This	enhanced	efficacy	of	soluble	CD80	is	probably	due	to	its	ability	to	simultaneously	 neutralize	 PD-L1-PD1	 suppression	 and	 to	 costimulate	 T	 cells,	 whereas	antibody	therapy	only	neutralizes	suppression.	Soluble	CD80	thus	provides	all	the	effects	of	a	“combination	therapy”	in	a	single	reagent.	The	 effectiveness	 of	 adoptive	 immunotherapies	 might	 be	 increased	 by	 T	 cell	 transduction	with	miR-155,	as	suggested	by	Luca	Gattinoni	(National	Institutes	of	Health,	Bethesda,	MD,	USA).	 In	 effect,	 he	 said,	 tumor-specific	 CD8+	 T	 cells	 that	 constitutively	 express	 miR-155	display	 sustained	 proliferation	 and	 cytokine	 production,	 which	 results	 in	 enhanced	 anti-tumor	 responses	even	 in	 the	absence	of	 lymphodepletion.	 In	particular,	 he	 found	 that	miR-155	 promoted	 the	 activity	 of	 Akt	 and	 Stat5,	 two	 pivotal	 pathways	 that	 are	 downstream	 of	homeostatic	cytokine	signaling,	by	restraining	the	expression	of	 the	Akt	 inhibitor	Ship1	and	multiple	negative	regulators	of	Stat5,	such	as	Socs1	and	Ptpn2.	Enforced	miR-155	expression	
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is	therefore	a	cell	 intrinsic	means	to	enhance	T	cell-based	immunotherapy	without	the	need	for	life-threatening,	lymphodepleting	maneuvers.	Cancer,	a	disease	of	the	elderly,	is	and	will	primarily	remain	a	problem	for	public	health	in	our	ageing	 societies	 and	 likely	 will	 become	 an	 epidemic.	 In	 this	 context,	 the	 identification	 of	suitable	 vaccine	 delivery	 systems	 for	 older	 individuals	 is	 important	 for	 increasing	 cancer	vaccine	efficacy.	Claudia	Gravekamp	(Albert	Einstein	College	of	Medicine,	Bronx,	New	York,	USA)	 discussed	 the	 crucial	 points	 of	 curing	 cancer	 via	 immunotherapy	 in	 older	 individuals	and	proposed	the	use	of	Listeria	monocytogenes	as	a	cancer	vaccine	delivery	system.		Listeria	acts	on	multiple	levels,	by	directly	infecting	tumor	cells	and	killing	tumor	cells	with	reactive	oxygen	 species	 (ROS),	 and	 Listeria	 infects	 MDSC	 resulting	 in	 the	 production	 of	 IL-12	 and	activation	 of	 T	 cells	 at	 young	 and	 old	 age.	 New	 immunization	 protocols	 in	 which	 low	concentrations	 of	 Listeria	 at	 short	 time	 intervals	 is	 administered,	 induce	 strong	 innate	immune	responses	that	assists	adaptive	immune	responses	to	the	tumor	cells.	This	resulted	in	a	 dramatic	 reduction	 in	 the	 number	 of	 metastases	 (90%	 compared	 to	 untreated	mice),	 in	 both	 young	 and	 old	 mice	 with	 metastatic	 breast	 cancer	 (4T1	syngeneic	model).	Very	interesting	results	were	also	presented	on	Radioactive	Listeria,	which	may	become	 a	 new	 alternative	 strategy	 for	 pancreatic	 cancer	 treatment	 in	 both	 young	 and	old,	 since	 it	 is	 able	 to	 eliminate	 pancreatic	 cancer	 in	 80%	 of	 treated	 mice	 and	 to	 almost	completely	remove	liver	metastases	in	a	Panc-2	mouse	model.	
	
Vaccines	and	other	immune	interventions	against	infection-associated	cancer	diseases	The	two	currently	available	HPV	vaccines	are	expensive	and	not	suitable	for	use	in	developing	countries.	Moreover,	they	are	mainly	based	on	the	generation	of	antibodies	to	the	virus	that	are	 able	 to	 eliminate	 the	 virus	 itself	 and	 therefore	 to	 prevent	 the	 development	 of	 cervical	cancer;	nevertheless	they	are	unable	to	eliminate	pre-existing	cancer	cells.	Therefore	there	is	still	a	need	for	therapeutic	vaccines	against	HPV	and	for	more	informative	preclinical	models.	Potentially	 therapeutic	 vaccines	 have	 been	 designed	 to	 generate	 T	 cells	 to	 recognize	 the	HPV16	antigens	(E6	and	E7)	expressed	by	the	cancer	cells.	Aldo	Venuti	and	coworkers	have	developed	 two	 new	 orthotopic	 mouse	 models	 of	 HPV-associated,	 ano-genital	 and	oropharyngeal	 cancers.	 Both	models	 are	 based	 on	 the	 use	 of	 transplantable	 cell	 lines	 that	express	luciferase.	The	bioluminescent	epithelial	TC-1	line,	which	expresses	HPV16	E6	and	E7	proteins,	is	injected	into	C57BL/6	mice	intravaginally	and	gives	rise	to	genital	tumors,	while	the	bioluminescent,	HPV16	E7	protein	expressing	AT-84	cell	 line	is	injected	into	the	floor	of	the	mouth	in	C3H	mice	via	an	extra-oral	route.	These	models	were	used	to	test	the	efficacy	of	
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gene	 based	 and	 plant	 derived	 vaccines	 against	 HPV16	 E7.	 New	models	 for	 other	 high	 risk	HPVs,	which	will	study	the	cross	activity	of	the	different	vaccines,	are	under	development.	
Marij	Welters	described	the	results	of	the	clinical	testing	of	an	HPV16	synthetic	long	peptide	(HPV16-SLP)	 based	 therapeutic	 vaccine.	 The	 vaccine	 proved	 to	 be	 clinical	 effective	 and	induced	 a	 HPV16-specific	 effector	 T-cell	 response	 in	 patients	 with	 HPV16-induced	premalignant	 vulvar	 lesions,	 a	 disease	which	 shows	 a	 spontaneous	 complete	 regression	 in	<2%	of	the	patients.	As	expected	from	their	immunosuppressed	immune	profile,	the	vaccine	induced	a	weaker	T-cell	 response	 in	 late	 stage	HPV16-induced	 cervical	 cancer	patients	 and	did	not	improve	clinical	outcome.	The	observations	that	late	stage	patients	display	transient	immune	profile	 normalization	 upon	 standard	 carboplatin-paclitaxel	 chemotherapy	 and	 that	the	HPV16-SLP	 vaccination	 and	 chemotherapy	 combination	 increases	 the	 cure	 rate	 of	mice	bearing	established	HPV16+	tumors	spurred	Welters	and	co-workers	to	start	a	clinical	trial	in	which	patients	receive	the	combined	treatment.		Adoptive	 transfer	of	autologous	genetically	modified	T	cells	 for	 the	 treatment	of	hepatitis	C	virus	 (HCV)	 infections	 was	 the	 focus	 of	 Timothy	 Spear's	 presentation	 (Loyola	 University	Chicago,	 Maywood,	 IL,	 USA).	 HCV	 infects	 approximately	 3%	 of	 the	 world	 population.	 The	rapidly	mutating	HCV	 genome	may	 lead	 to	 immune	 escape	 variants,	 chronic	 infections	 and	eventually	 hepatocellular	 carcinoma	 (HCC)	 in	 some	patients.	 Conversely,	 a	 variety	 of	 T	 cell	receptors	 (TCR)	 with	 the	 capacity	 to	 recognize	 many	 viral	 protein	 epitopes	 may	 exist	 in	patients	 with	 a	 resolved	 HCV	 infection.	 Indeed,	 Spear	 and	 co-workers	 isolated	 an	 HLA-A2	restricted	TCR	 specific	 for	 the	HCV	peptide	NS3:1406-1415,	 from	 an	HCV+	HLA-A2-	 patient	who	received	an	HLA-A2+	 liver	allograft.	 	Normal	PBL-derived	T	cells	engineered	to	express	this	 high-affinity	 TCR	 recognize	 the	 wild-type	 peptide	 and	 naturally	 occurring	 mutant	peptides	 expressed	 by	 HCC	 cells	 in	 a	 CD8-independent	manner.	 Adoptive	 transfer	 of	 these	engineered	 T	 cells	 can	mediate	 human	HCC	 tumor	 regression	 in	 a	mouse	 xenograft	model.	Therefore,	 HCV-reactive	 TCR	 gene	 modified	 T	 cells	 may	 be	 a	 promising	 form	 of	 clinical	therapy	for	treating	HCV	infection	and	associated	HCC.			
Comparative	oncology	in	translational	medicine	In	 2003	 the	 National	 Cancer	 Institute's	 Center	 for	 Cancer	 Research	 of	 the	 United	 States	launched	 the	 Comparative	 Oncology	 Program	 to	 help	 researchers	 better	 understand	 the	biology	of	cancer	and	improve	the	assessment	of	novel	treatments	for	humans	by	treating	pet	animals	 -	 primarily	 cats	 and	 dogs	 -	 with	 naturally	 occurring	 cancer.	 Philip	 J.	 Bergman	(Katonah-Bedford	 Veterinary	 Center,	 Bedford	 Hills,	 NY,	 USA)	 espoused	 the	 translational	
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power	of	cancer	vaccine	trials	in	client-owned	pets	by	summarizing	the	data	he	obtained	from	dogs	with	 canine	malignant	melanoma	 (CMM)	using	ONCEPT,	USDA	approved	DNA	vaccine	against	 tyrosinase	 commercialized	 by	 Merial.	 Various	 clinical	 trials	 in	 CMM	 patients	demonstrate	that	ONCEPT	is	safe,	induces	specific	anti-tyrosinase	humoral	and	cell-mediated	immune	responses	and	is	therapeutic	in	stage	II/III	local-regional	controlled	disease.	CMM	are	spontaneous	 cancers	 that	 develop	 in	 outbred	 immuno-competent	 hosts	 that	 share	 living	environments	and	cancer-bearing	ages	with	us.	Both	CMM	and	advanced	human	melanoma	are	 initially	 treated	with	 aggressive	 local	 therapies	 including	 surgery	 and/or	 radiotherapy;	however,	 the	 development	 of	 systemic	metastatic	 disease	 is	 very	 common.	 Based	 on	 these	similarities,	 CMM	appears	 to	 be	 a	 clinically	 faithful	model	 for	 human	malignant	melanoma.	The	results	obtained	with	ONCEPT	are	thus	of	high	translational	value.	
Guillermo	 Marshall	 (Departamento	 de	 Computacion,	 Universidad	 de	 Buenos	 Aires,	Argentina)	 briefly	 discussed	 results	 of	 electrochemotherapy	 (ECT	 –	 a	 combination	 of	membrane	permeabilisation	by	high	voltage	electric	pulses	and	injection	of	cancer	drugs	that	have	 limited	 access	 to	 the	 cytosol)	 performed	 in	 pet	 animals,	 affected	 by	 different	 solid	tumors.	 He	 pointed-out	 that	 ECT	 not	 only	 allows	 efficient	 treatment	 of	 tumors	 with	 non-permeant	cytotoxic	drugs,	 it	also	induces	per	se	a	 low	level	humoral	 immune	response.	One	dog	affected	by	a	grade	2	desmoplastic	melanoma,	another	one	affected	by	a	grade	3	giant	cell	sarcoma,	as	well	as	a	cat	with	a	squamous	cell	carcinoma,	have	been	treated	with	bleomycin	administered	into	the	tumors	by	ECT.		Due	to	the	promising	results	revealed	in	the	two-three	months	 follow-up,	 Marshall	 and	 co-workers	 are	 planning	 to	 couple	 ECT	 with	 gene	electrotransfer	protocols	based	on	immunotherapy	with	plasmid	vectors	expressing	IL-2	and	IL-12.		
	DNA	vaccination	and	gene	electrotransfer	Lectures	in	the	section	co-organized	by	COST	TD1104	Action	(www.electroporation.net)	were	organized	in	such	a	way	as	to	provide	a	complete	range	of	views	on	electrotransfer,	from	its	basic	concepts	(lab-bench)	to	the	most	efficient	patient	protocols	(bench-bedside).	Guillermo	
Marshall	described	the	associations	between	electric	 fields,	pH	fronts	and	tissue	damage	in	gene	electrotransfer	protocols.	He	presented	examples	of	in	vitro,	in	silico	and	in	vivo	pH	front	modeling	 and	 showed	 evidence	 of	 pH	 fronts	 generated	 by	 local	 electric	 field	 application,	suggesting	 they	are	principal	causes	of	 the	 tissue	damage.	 Justin	Teissié	 (CNRS-Institute	of	Pharmacology	 and	 Structural	 Biology,	 Toulouse,	 France)	 briefly	 summarized	 35	 years	 of	studies	 on	 membrane	 permeabilisation	 by	 high	 voltage	 electric	 pulse	 mechanisms	 with	
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respect	to	cell	membrane	structural	changes	and	the	molecular	transport	of	differently	sized	nucleic	 acids.	 He	 discussed	 how	 the	 high	 voltage	 electric	 pulses	 (EP)	 gives	 rise	 to	 cellular	membrane	structural	changes	and	to	molecular	transport,	pointing	out	EP	is	a	reversible	but	stressful	event	for	the	cells,	which	undergo	stretching	and	swelling	phenomena.	The	delivery	of	 small	 siRNA	 and	 larger	 pDNA	 with	 respect	 to	 the	 delay	 between	 the	 membrane	permeabilization	and	transport	into	the	cytoplasm	and	then	into	the	nucleus	of	the	cells	was	also	reported.	He	demonstrated	that	only	properly	selected	electric	pulse	physical	parameters	can	provide	efficient	nucleic	acid	transfer	and	good	cell	survival.	
Damijan	 Miklavcic	 (University	 of	 Ljubljana,	 Faculty	 of	 Electrical	 Engineering,	 Slovenia)	presented	data	on	plasmid	DNA	transport	across	the	membrane,	the	effects	of	pulse	polarity	in	DNA	transfer	and	 the	 importance	of	electrode	selection	 for	successful	 in	vitro	 and	 in	vivo	gene	 transfer	 protocols.	 He	 showed	 that	 electric	 field	 distribution	 depends	 on	 electrode	geometry,	placement	and	tissue	anatomy,	and	proposed	predictive	mathematical	models	 for	determination	 of	 electric	 field	 distribution,	 useful	 for	 the	 success	 of	 electrotransfer	treatments.	The	 importance	of	 the	 tissue	geometry	and	 its	passive	electrical	properties	 that	influence	 the	 effects	 of	 the	 applied	 pulse	 amplitude	 has	 been	 also	 discussed.	 Thanks	 to	 a	better	understanding	of	the	mechanisms	governing	the	electrotransfer,	an	accurate	choice	of	electrical	parameters	to	be	applied	with	appropriate	electrodes	chosen	among	a	large	variety,	is	now	possible.		
Gregor	 Sersa	 (Institute	 of	 Oncology,	 Ljubljana,	 Slovenia)	 presented	 the	 results	 from	therapeutic	electrogene	therapy	protocols	for	the	delivery	of	IL-12	in	cancer	treatment.	Data	on	 local	 intratumoral	and	 intramuscular	plasmid	DNA	delivery,	peritumoral	or	 intratumoral	gene	 therapy	 combined	 with	 tumor	 irradiation,	 human	 clinical	 trials	 and	 veterinary	applications	were	discussed.	He	demonstrated	the	effectiveness	of	IL-12	electrogene	therapy	on	 subcutaneous	 solid	 tumors	 and	 in	 induced	 lung	 metastasis.	 Data	 on	 the	 successful	combination	 of	 electrochemotherapy	 and	 electrogene	 IL-12-based	 therapy	 treatment	 in	mastocytoma-affected	 dogs	 were	 also	 presented.	 The	 importance	 of	 electrode	 design,	 the	proper	choice	of	electric	pulse	parameters	 to	obtaining	 favorable	 therapeutic	outcomes	and	the	role	of	the	comparative	oncology	was	stressed.					
The	HLA	ligandome	analysis	to	identify	new	vaccination	targets	The	loss	of	MHC	class	I	expression	is	a	widespread	mechanism	in	tumor	escape	from	CD8+	T	cell	 responses	 and	 one	 of	 the	 main	 reasons	 for	 tumor	 resistance	 to	 immunotherapy.	Nevertheless,	 in	many	tumors	MHC	class	I	defects	are	“soft”,	reversible,	and	MHC	class	I	cell	
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surface	 expression	 recovery	 can	 be	 achieved	 via	 different	 methods,	 e.g.	 cytokines,	radiotherapy	 and	 chemotherapy,	 as	 reviewed	 by	 Federico	 Garrido	 (Department	 of	Immunology,	Universidad	de	Granada,	 Spain)	 in	his	 lecture.	 In	 these	 cases,	 immunotherapy	may	 result	 in	 a	T	 cell	mediated	 tumor	 rejection.	Therefore,	peptides	naturally	presented	as	HLA	ligands	on	tumor	cells	may	represent	ideal	vaccine	antigens	to	induce	a	T	cell	response.	To	 this	 end,	 Janet	 Peper	 (Department	 of	 Immunology,	 University	 of	 Tübingen.,	 Germany)	conducted	an	HLA	ligandome	analysis	on	6	ovarian	cancer	samples	and	tested	the	ability	of	the	 identified	 peptides	 to	 prime	 CD8+	 T	 cells	 from	 healthy	 HLA-matched	 blood	 donors.	Immunogenic	 HLA	 ligands	 derived	 from	 histone	 deacetylases	 (HDAC)	 1	 and	 2	 were	represented	 in	 all	 analyzed	 tumor	 samples.	 HDAC	 molecules	 are	 overexpressed	 in	 many	different	 cancer	 types,	 including	 ovarian	 cancer;	 they	 increase	 cell	 proliferation,	 cell	migration,	angiogenesis	and	invasion	by	reducing	tumor	suppressor	gene	transcription.	HDAC	inhibitors	 are	 currently	 being	 tested	 in	 several	 clinical	 tumor	 therapy	 trials	 and	 are	 giving	promising	 results.	 Hence,	 HDAC	 are	 suitable	 targets	 for	 T-cell	 mediated	 immunotherapy.	Peper	 and	 co-workers	 are	 planning	 to	 use	 immunogenic	 HDAC1/2	 derived	 peptides	 in	 an	upcoming	phase	I/II	vaccination	trial	in	ovarian	cancer	patients.			
Monitoring	of	cancer-specific	B	cell	responses	The	 Satellite	 Symposium	 sponsored	 by	 Cellular	 Technology	 Limited	 –	 CTL	 gave	 Paul	 V.	
Lehmann	(President	and	CEO	of	Cellular	Technology	Limited	–	CTL,	Shaker	Heights,	OH,	USA)	the	 opportunity	 to	 highlight	 the	 potential	 importance	 of	 monitoring	 cancer-specific	 B	 cell	responses	in	early	diagnosis	and	the	prediction	of	cancer	vaccine	responses.	Serum	antibodies	are	not	fully	reflective	of	B	cell	immunity	as	their	production	results	from	random	memory	B	cell	activation,	they	can	be	absorbed	by	a	persisting	antigen	and	because	they	can	be	locally	produced	if	the	antigen	persists.	For	these	reasons	it	is	important	to	directly	monitor	antigen	specific	B	cells.	While	antigen	specific	T	cells	can	be	stained	by	tetramers	and	similar	‘mers’,	B	cell	staining,	using	labeled	antigens,	has	not	so	far	been	successful.	Therefore,	ELISPOT	is	still	the	only	way	of	identifying	antigen	specific	B	cells	and	CTL	has	developed	protocols	and	tools	for	 this	 purpose.	 This	 interesting	 approach	 has	 been	 extensively	 used	 in	 monitoring	autoimmune	diseases	and	now	is	available	for	cancer	studies.		
Cancer	stem	cells	as	strategic	cancer	vaccination	targets		Most	 tumors	display	 an	 intrinsic	 cell	 hierarchy,	with	 a	 small	 population	of	 undifferentiated	tumorigenic	 cells	 -	 the	 so-called	 cancer	 stem	cells	 (CSC)	 -	 at	 the	 apex	of	 the	hierarchy.	 CSC	
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posses	all	the	unique	biological	properties	necessary	to	maintain	and	spread	tumors	as	well	as	 displaying	 a	 plethora	 of	 cytoprotective	mechanisms	which	make	 them	 therapy	 resistant.	They	are	thus	a	reservoir	for	disease	relapse	and	metastatic	evolution.	CSC	are	consequently	a	strategic	 target	 for	 treatments	 that	 interrupt	 tumor	 cell	 generation	 and	 dissemination,	 as	pointed	 out	 by	 Giorgio	 Parmiani	 (Division	 of	 Molecular	 Oncology,	 San	 Raffaele	 Hospital,	Milan,	Italy)	in	his	closing	lecture.	The	identification	of	immunologically	relevant	markers	that	are	 expressed	 on	 CSC	 may	 thus	 lead	 to	 effective	 immunotherapies.	 Parmiani	 suggested	possible	 targets	 that	 include	 both	 differentiation	 antigens	 (i.e.	 MUC1,	 carcino-embryonic	antigen,	 tyrosinase,	 survivin,	 aldehyde	 dehydrogenase,	 EpCAM,	 etc.)	 and	 tumor	 specific	mutated	 antigens.	 Indeed,	 CSC	 may	 contain	 many	 missense	 somatic	 mutations	 that	 can	generate	 new	 T	 cell	 epitopes.	 These	 mutations	 are	 now	 detectable	 thanks	 to	 new	 deep	sequencing	technology,	making	the	preparation	of	individual,	mutated	peptide-based	vaccines	possible.	 Nevertheless,	 CSC	 have	 various	 mechanisms	 that	 suppress	 any	 vaccine-induced	immune	response	(i.e.	indoleamine	2,3-deoxygenase-1,	IL-4,	PD-L1,	IL-10,	B7-H3,	TGF-β,	Fas-L).	 Counteracting	 these	 mechanisms	 is	 thus	 necessary	 for	 the	 success	 of	 anti-CSC	immunotherapies.		
Maarten	Ligtenberg	(Karolinska	Institutet,	Stockholm,	Sweden)	described	the	effects	of	DNA	vaccination	 against	 a	 broadly	 expressed	 tumor-associated	 antigen,	 Cripto-1,	 whose	expression	is	increased	in	breast	CSC.	Cripto-1	is	a	cell	membrane	tethered	glycoprotein	that	plays	 a	 critical	 role	during	 embryogenesis	 by	 regulating	 left-right	 axis	 development.	 Poorly	expressed	 in	normal	 tissues,	 it	 is	 overexpressed	on	melanoma,	breast,	 colon,	 pancreas	 lung	and	 many	 other	 human	 cancers	 where	 it	 induces	 cell	 proliferation,	 migration,	 epithelial-mesenchymal	transition	and	angiogenesis.	Plasmid	DNA	encoding	mouse	Cripto-1	generates	a	protective	adaptive	immune	response	in	B16F10	and	4T1	models,	reduces	metastatic	burden	in	Her2	transgenic	(BALB-neuT)	mice	and	specifically	 limits	cancer	stem	cell	growth	 in	vivo.	These	results	demonstrate	that	Cripto-1	is	an	immunologically	relevant	marker	of	CSC	and	a	good	target	for	the	development	of	prophylactic	and	therapeutic	tumor	vaccines.			
Awards	The	European	Federation	of	 Immunological	 Societies	 (EFIS)	 granted	 two	Meeting	Bursaries	that	went	to	Tania	Lahera	(National	Institute	of	Oncology,	Havana,	Cuba)	and	Constantinos	
Televantos	(The	University	of	Nottingham,	UK).	The	two	EACR	Poster	Prizes	were	awarded	to	 Regina	 Heidenreich	 (CureVac,	 GmbH,	 Tübingen,	 Germany)	 and	 Belinda	 Sanchez	
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Ramirez	 (Center	 of	 Molecular	 Immunology,	 Havana,	 Cuba).	 The	 committee	 for	 poster	evaluation	also	addressed	a	special	mention	to	Stefano	Ugel	(University	of	Verona,	Italy).	 
Conclusion	The	 PIVAC-14	 conference	 brought	 together	 translational	 and	 clinical	 oncologists	 and	immunologists	who	provided	an	up-to-date	overview	of	many	aspects	of	tumor	immunology	and	of	 the	most	recent	advances	 in	active	cancer	vaccination	and	adoptive	cell	 therapy.	The	data	 from	 retrospective	 analysis	 of	 patients	 enrolled	 in	 phase	 I/II	 clinical	 trials	 has	highlighted	 the	 possibility	 to	 identify	 immune	 parameters	 that	 may	 discriminate	 between	responders	 and	 non-responders.	 Most	 of	 these	 parameters	 are	 related	 to	 tumor	 induced	immune	 suppression,	 further	 confirming	 the	 need	 to	 move	 towards	 combinatorial	immunotherapeutic	approaches	able	to	counteract	immune	suppression	and,	where	possible,	towards	 cancer	 immune	 prevention.	 Graham	 Pawelec	 (Centre	 for	 Medical	 Research,	University	 of	 Tübingen,	 Germany)	 concluded	 his	 summing	 up	 of	 the	 meeting	 with	 the	announcement	that	the	15th	PIVAC	edition	conference	will	take	place	in	Tübingen,	Germany,	on	October	6-8,	2015.		
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